News Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Market Closed - Australian S.E. Other stock markets 02:10:05 2024-04-29 am EDT			5-day change	1st Jan Change
0.032 ^AUD	+6.67%		+6.67%	+45.45%

Apr. 22	Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	CI
Apr. 22	Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	Apr. 22	CI
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%	Apr. 21	MT
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial	Apr. 15	CI
Actinogen Doses First Patient in Phase 2b Alzheimer’s Disease Trial; Shares Rally 16%	Apr. 14	MT
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25	MT
Actinogen Medical Initiates Final Enrolment Phase for XanaCIDD Depression Trial; Shares Rise 3%	Mar. 07	MT
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment	Feb. 15	MT
Actinogen Medical Activates First Trial Site for Phase 2B Alzheimer’s Disease Trial	Dec. 20	MT
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial	Nov. 28	CI
Actinogen Medical's XanaCIDD Trial Enrolment Surpasses 50% Milestone	Nov. 28	MT
Actinogen Medical Receives AU$4.8 Million R&D Tax Refund	Nov. 28	MT
Actinogen Medical Names CFO	Nov. 07	MT
Actinogen Medical Limited Announces CFO Changes	Nov. 07	CI
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston	23-10-13	CI
Actinogen Medical Redesigns Phase 2b Trial of Alzheimer's Disease Drug	23-09-27	MT
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results	23-09-26	CI
Actinogen Medical Completes AU$10 Rights Issue	23-09-07	MT
Actinogen Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Rights Issue: 100 new shares @ 0.025 AUD for 454 existing shares	23-08-10	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Summary

Filters